Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Development of Two Stable Green Nanoformulations With Potent Anticancer Properties Publisher



Ghanbariasad A1, 2 ; Osanloo M2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Iran
  2. 2. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
  3. 3. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Iran

Source: Nanomedicine Research Journal Published:2020


Abstract

The most common cause of cancer death among women is breast cancer thus, developing new drugs is crucial. Essential oils (EO)s with a wide range of bioactivities, such as anticancer effects, have provided a valuable source for this purpose. In this study, components of two medicinally important EOs were identified using GC-MS analysis. Moreover, antioxidant effects, as well as anticancer properties, were evaluated. The EOs formulated into nanoemulsion using the spontaneous emulsification approach, separately. Comprehensive stability tests were performed to select the optimum nanoemulsions of each EO. Anticancer effect of the most stable nanoemulsion of Zataria multiflora with a particle size of 43 ± 4 nm (PDI 0.4 ± 0.2 and SPAN 0.6 ± 0.1) was significantly better non-formulated form against four human breast cancer cell lines, MCF-7, MDA-MB-175, MDA-MB-231, and MDA-MB-468. Interestingly, the anticancer effect of Artemisia dracunculus nanoemulsion (16 ± 4 nm, 0.2 ± 0.1, and 0.4 ± 0.1) was also significantly improved in compassion to the non-formulated EO. Considering the results, prepared nanoemulsions could be used as supplementary drugs or food additives. © This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.